Search

Your search keyword '"tumor-infiltrating B cells"' showing total 3 results
Start Over Descriptor "tumor-infiltrating B cells" Journal oncoimmunology
3 results on '"tumor-infiltrating B cells"'

1. Immunotargeting of tumor subpopulations in melanoma patients A paradigm shift in therapy approaches.

Author

Maurer, Margarita, Somasundaram, Rajasekharan, Herlyn, Meenhard, and Wagner, Stephan N.

Subjects
*MELANOMA, *CANCER cells, *CANCER relapse, *B cells, *IMMUNOGLOBULINS, *RITUXIMAB, *PATIENTS
Abstract

Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of Stage IV melanoma patients may potentially benefit from an adjuvant treatment using the anti-CD20 antibody rituximab. [ABSTRACT FROM AUTHOR]

Published
2012
Full Text
View/download PDF

2. Tumor-infiltrating B cells

Author

Linnebacher, Michael and Maletzki, Claudia

Subjects
tumor host interaction, tumor-infiltrating lymphocytes, B cell subtypes, tumor-infiltrating B cells, tumor immunology, Author's View
Abstract

B cells infiltrating into solid tumors are poorly investigated despite their described positive prognostic value. Whether this antitumor potential comes from either the antigen presentation or the antibody production capacity of B cells, or both, is unknown. Our recently published method on tumor-infiltrating B lymphocyte cloning may prove helpful in unraveling the actual relevance of these cells for tumor development and response to therapy.

Published
2012

3. Immunotargeting of tumor subpopulations in melanoma patients: A paradigm shift in therapy approaches

Author

Stephan N. Wagner, Margarita Maurer, Rajasekharan Somasundaram, and Meenhard Herlyn

Subjects
Oncology, medicine.medical_specialty, medicine.medical_treatment, Immunology, tumor-infiltrating B cells, Text mining, rituximab, Internal medicine, hemic and lymphatic diseases, medicine, melanoma, Immunology and Allergy, CD20, Author's View, tumor-initiating subpopulations, biology, business.industry, Melanoma, medicine.disease, Tumor recurrence, biology.protein, Stage iv melanoma, adjuvant immunotherapy, Rituximab, Antibody, business, Adjuvant, medicine.drug
Abstract

Several melanoma cell subpopulations with tumor-initiating and/or tumor-maintaining properties exist that may contribute to chemoresistance and tumor recurrence after standard therapies. One of these subpopulations expresses a B-cell marker, CD20. In a small pilot trial, we showed that a subset of Stage IV melanoma patients may potentially benefit from an adjuvant treatment using the anti-CD20 antibody rituximab.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results